TVTX
Travere Therapeutics, Inc.Company Information
- Company Name
- Travere Therapeutics, Inc.
- CIK
- CIK0001438533
- Category
- Large accelerated filer
- Ticker: Exchange
- TVTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TVTX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-17
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,230,482
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 103,142,084
- Shares outstanding
- 93,479,416
- Ownership
- 110.34%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- 17.23%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 118 | 78 | 93 | 111 | 75 | 62 | 59 | 36 | 32 | 43 | 58 | 144 | ||||||
| Available For Sale Securities Debt Securities | 371 | 186 | 230 | 144 | 244 | 260 | 312 | 241 | 293 | 398 | 509 | 490 | ||||||
| Accounts Receivable Net Current | 81 | 87 | 80 | 83 | 39 | 34 | 27 | 25 | 24 | 23 | 21 | 15 | ||||||
| Inventory Net | - | - | 36 | - | - | - | 42 | - | - | - | 9 | 21 | ||||||
| Inventory Gross | 8 | 6 | 6 | 6 | 4 | 4 | 6 | 6 | 6 | 5 | - | - | ||||||
| Prepaid Expense And Other Assets Current | 37 | 34 | 29 | 28 | 17 | 14 | 13 | 16 | 13 | 13 | 19 | 16 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets Current | 615 | 393 | 438 | 371 | 380 | 374 | 417 | 325 | 369 | 481 | 617 | 686 | ||||||
| Inventory Noncurrent | 32 | 31 | 30 | 32 | 34 | 34 | 36 | 37 | 37 | 38 | 31 | - | ||||||
| Property Plant And Equipment Net | 3 | 4 | 4 | 4 | 5 | 5 | 5 | 6 | 7 | 7 | 7 | 8 | ||||||
| Operating Lease Right Of Use Asset | 9 | 10 | 11 | 11 | 12 | 13 | 14 | 16 | 16 | 17 | 18 | 19 | ||||||
| Intangible Assets Net Excluding Goodwill | 132 | 110 | 114 | 109 | 106 | 104 | 104 | 104 | 105 | 101 | 104 | 107 | ||||||
| Other Assets Noncurrent | 9 | 8 | 9 | 10 | 20 | 19 | 18 | 17 | 17 | 19 | 11 | 13 | ||||||
| Assets | 799 | 555 | 605 | 539 | 555 | 549 | 594 | 504 | 551 | 664 | 789 | 833 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 7 | 13 | 25 | 18 | 19 | 15 | 24 | 23 | 26 | 17 | 42 | 25 | ||||||
| Accrued Liabilities Current | 136 | 104 | 126 | 106 | 82 | 77 | 86 | 84 | 80 | 140 | 119 | 96 | ||||||
| Convertible Debt Current | - | - | 0 | 0 | 69 | 69 | 69 | 69 | - | - | 0 | - | ||||||
| Operating Lease Liability Current | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | 3 | 4 | 5 | 6 | 7 | 9 | ||||||
| Other Liabilities Current | 2 | 2 | 3 | 5 | 14 | 16 | 17 | 5 | 5 | 5 | 5 | 5 | ||||||
| Liabilities Current | 152 | 125 | 160 | 135 | 190 | 182 | 201 | 190 | 121 | 173 | 178 | 139 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Convertible Debt Noncurrent | - | - | 312 | 311 | 311 | 311 | 310 | 310 | 378 | 378 | 377 | 377 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | - | - | - | 0 | 1 | 2 | 5 | ||||||
| Convertible Debt | 603 | 312 | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 8 | 10 | 11 | 13 | 14 | 16 | 17 | 19 | 20 | 21 | 23 | 24 | ||||||
| Other Liabilities Noncurrent | 12 | 9 | 8 | 6 | 8 | 7 | 7 | 16 | 17 | 16 | 10 | 8 | ||||||
| Liabilities | 775 | 456 | 490 | 465 | 523 | 516 | 535 | 535 | 536 | 589 | 588 | 553 | ||||||
Stockholders Equity | ||||||||||||||||||
| Liabilities Of Disposal Group Including Discontinued Operation Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,570 | 1,610 | 1,589 | 1,550 | 1,535 | 1,522 | 1,506 | 1,357 | 1,349 | 1,338 | 1,328 | 1,319 | ||||||
| Retained Earnings Accumulated Deficit | -1,545 | -1,510 | -1,473 | -1,475 | -1,501 | -1,488 | -1,447 | -1,387 | -1,332 | -1,262 | -1,126 | -1,035 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -1 | -1 | -1 | -0 | -1 | -2 | -2 | -1 | -4 | ||||||
| Stockholders Equity | 25 | 99 | 115 | 74 | 33 | 33 | 59 | -30 | 15 | 74 | 201 | 280 | ||||||
| Liabilities And Stockholders Equity | 799 | 555 | 605 | 539 | 555 | 549 | 594 | 504 | 551 | 664 | 789 | 833 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 94 | 92 | 91 | 89 | 89 | 89 | 87 | 78 | 76 | 76 | 75 | 75 | ||||||
| Shares Outstanding | 94 | 92 | 91 | 89 | 89 | 89 | 87 | 78 | 76 | 76 | 75 | 75 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTravere Therapeutics, Inc. (TVTX) — SEC Financial Statements & Analysis
Travere Therapeutics, Inc. (TVTX) is a pharmaceutical preparations company, incorporated in CA. Travere Therapeutics, Inc. trades on Nasdaq as: TVTX. Travere Therapeutics, Inc. (TVTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Travere Therapeutics, Inc. carries a market cap of $5.31B, a P/E ratio of -122.18x, a P/B ratio of 216.56x, a P/S ratio of 8.98x, an enterprise value of $5.80B, and an EV/EBITDA multiple of 252.97x. On profitability, it posts a gross margin of 98.60%, an operating margin of -6.84%, a net margin of -7.35%, a Return on Equity (ROE) of -151.79%, a Return on Assets (ROA) of -6.42%, and a Return on Invested Capital (ROIC) of -9.27%. Per share, it reports EPS of $-0.46, diluted EPS of $-0.46, free cash flow per share of $0.32, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 77.12% year-over-year, net income growth of -74.29% year-over-year, and EPS growth of -75.54% year-over-year. On the balance sheet, it maintains a current ratio of 4.05x, a quick ratio of 3.75x, working capital of $463.12M, a debt-to-equity ratio of 31.60x, a debt ratio of 0.97, an interest coverage ratio of -4.27x, free cash flow of $30.07M (TTM), and net debt of $485.05M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.31B
- P/E TTM
- -122.18x
- EPS TTM
- $-0.46
- P/B TTM
- 216.56x
- ROE TTM
- -151.79%
- ROA TTM
- -6.42%
- Debt To Equity
- 31.60x
- Free Cash Flow TTM
- $30.07M
- Net Revenue TTM Growth 1Y
- 77.12%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Travere Therapeutics, Inc. in?
Travere Therapeutics, Inc. (TVTX) operates in the Pharmaceutical Preparations industry.
What exchange does TVTX trade on?
Travere Therapeutics, Inc. (TVTX) trades on the Nasdaq.
Where is Travere Therapeutics, Inc. incorporated?
Travere Therapeutics, Inc. is incorporated in CA.
When was Travere Therapeutics, Inc. (TVTX)'s most recent SEC filing?
Travere Therapeutics, Inc. (TVTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is TVTX's market cap?
Travere Therapeutics, Inc. (TVTX) has a market capitalization of $5.31B as of 2026-06-30.
What is TVTX's EPS (earnings per share)?
Travere Therapeutics, Inc. (TVTX)'s trailing twelve month EPS is $-0.46 as of 2026-06-30.
What is TVTX's ROE (return on equity)?
Travere Therapeutics, Inc. (TVTX)'s trailing twelve month Return on Equity (ROE) is -151.79% as of 2026-06-30.
What is TVTX's ROA (return on assets)?
Travere Therapeutics, Inc. (TVTX)'s trailing twelve month Return on Assets (ROA) is -6.42% as of 2026-06-30.
What is TVTX's ROIC (return on invested capital)?
Travere Therapeutics, Inc. (TVTX)'s trailing twelve month Return on Invested Capital (ROIC) is -9.27% as of 2026-06-30.
What is TVTX's EV/EBITDA?
Travere Therapeutics, Inc. (TVTX)'s trailing twelve month EV/EBITDA is 252.97x as of 2026-06-30.